甲磺酸达拉非尼 T8474

Product Introduction
Bioactivity


英文名: Dabrafenib Mesylate

描述: Dabrafenib Mesylate (GSK2118436 Mesylate) 是一种ATP 竞争型Raf 抑制剂，抑制C-Raf 和B-RafV600E 的IC50分别为 5 和 0.6 nM。

体外活性: In human endothelial cells, Dabrafenib inhibits the release of HMGB1 and down-regulates the HMGB1-dependent inflammatory response by enhancing the expression of cell adhesion molecules (CAM)[1]

存储条件: keep away from direct sunlightPowder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 34 mg/mL (55.22 mM)


关键字: Dabrafenib | Raf kinases | Inhibitor | GSK2118436 | Raf | inhibit | GSK 2118436 Mesylate | GSK 2118436 | GSK-2118436 | GSK-2118436 Mesylate | Dabrafenib Mesylate

相关产品: AD80 | PLX-4720 | Raf inhibitor 1 dihydrochloride | Uplarafenib | PLX8394 | K-Ras(G12C) inhibitor 12 | ARS-853 | Indirubin | Ro 5126766 | Zabofloxacin hydrochloride

相关库: Drug Repurposing Compound Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Drug Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Active Compound Library | Tyrosine Kinase Inhibitor Library | Highly Selective Inhibitor Library | EMA Approved Drug Library

甲磺酸达拉非尼 T8474信息由TargetMol中国为您提供，如您想了解更多关于甲磺酸达拉非尼 T8474报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途